## In the Claims:

This listing of claims will replace all prior versions of claims in the application. Please cancel claim 3 without prejudice to its presentation in another application.

- 1. (original) A compound 8 to 80 nucleobases in length targeted to a nucleic acid molecule encoding hydroxysteroid 11-beta dehydrogenase 1, wherein said compound specifically hybridizes with said nucleic acid molecule encoding hydroxysteroid 11-beta dehydrogenase 1 and inhibits the expression of hydroxysteroid 11-beta dehydrogenase 1.
- 2. (original) The compound of claim 1 which is an antisense oligonucleotide.
- 3. (canceled).
- 4. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
- 5. (original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
- 6. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
- 7. (original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
- 8. (original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.

## **DOCKET NO.: ISIS0048-101 (RTS-0428USA)**

- 9. (original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.
- 10. (original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
- 11. (original) A compound 8 to 80 nucleobases in length which specifically hybridizes with at least an 8-nucleobase portion of an active site on a nucleic acid molecule encoding hydroxysteroid 11-beta dehydrogenase 1.
- 12. (original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
- 13. (original) The composition of claim 12 further comprising a colloidal dispersion system.
- 14. (original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
- 15. (original) A method of inhibiting the expression of hydroxysteroid 11-beta dehydrogenase 1 in cells or tissues comprising contacting said cells or tissues with the compound of claim 1 so that expression of hydroxysteroid 11-beta dehydrogenase 1 is inhibited.
- 16. (original) A method of treating an animal having a disease or condition associated with hydroxysteroid 11-beta dehydrogenase 1 comprising administering to said animal a therapeutically or prophylactically effective amount of the compound of claim 1 so that expression of hydroxysteroid 11-beta dehydrogenase 1 is inhibited.
- 17. (original) The method of claim 16 wherein the disease or condition is a metabolic disorder.

## **DOCKET NO.: ISIS0048-101 (RTS-0428USA)**

**PATENT** 

- 18. (original) The method of claim 17 wherein the metabolic disorder is selected from the group consisting of obesity, diabetes, atherosclerosis and hyperlipidemia.
- 19. (original) The method of claim 16 wherein the disease or condition is osteoporosis.
- 20. (original) The method of claim 16 wherein the disease or condition is depression.